Login / Signup

Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.

Albert Muñoz-VendrellPablo Arroyo-PereiroIsabel LeónLaura BauElisabet MatasAntonio Martínez-YélamosSergio Martínez-YélamosLucía Romero-Pinel
Published in: Journal of neurology (2023)
The JCV status can be used as a natural experiment to compare treatment arms with a low selection bias. In our study, switching to OCR versus NTZ continuation led to similar disease activity outcomes.
Keyphrases